In a major breakthrough in cancer research, in a prospective phase 2 study, 18 rectal cancer patients saw their tumors completely vanish after taking the drug dostarlimab for six months. Cancer was undetectable in follow-up tests by endoscopy, PET and MRI scans, positron emission tomography, or physical exam!
Dr. Luis A. Diaz of Memorial Sloan Kettering Cancer Center, where the study was carried out, said, “This is the first time this has happened in the history of cancer.”
Dostarlimab is a monoclonal antibody that is marketed under the brand name Jemperli. The drug was approved in the U.S. and the E.U. in April 2021 for treating recurrent or advanced endometrial cancer with deficient mismatch repair (dMMR).
Market Data 
Markets 
AI
